Myelofibrosis Market Growth Analysis By DelveInsight

Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibers. Mutations in the JAK2, MPL, CALR, and TET2 genes are associated with most cases of primary myelofibrosis. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.

• According to the National Organization for Rare Disorders, Primary myelofibrosis is a chronic blood disorder that affects males and females in equal numbers. It can occur at any age although it usually affects individuals more than 50 years of age. The median age at diagnosis is approximately 65. The incidence is estimated to be 1.5 cases per 100,000 people in the United States. The worldwide incidence is unknown. When primary myelofibrosis affects children, it is usually before three years of age.
• According to the National Institute of Health, Primary Myelofibrosis is a rare condition that affects approximately 1 in 500,000 people worldwide.
• According to a study conducted by Moular O. et al., titled, “Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union”, the incidence rate of MF across the EU ranged from 0.1 / 100,000 to 1 / 100,000 per year in 2014.
• According to the Orphanet, the annual incidence of primary myelofibrosis (PMF) is approximately 1 case per 100,000 individuals, although an increased Incidence is noted in Ashkenazi Jews. Severity and prognosis are variables depending on the affected genes and symptoms.

DelveInsight's "Myelofibrosis Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Myelofibrosis market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Myelofibrosis market shares of the individual therapies, a detailed current Myelofibrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market. 

Myelofibrosis Market Growth

The Myelofibrosis market analysis section of the report helps to understand the current and forecasted Myelofibrosis market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers.  The report gives complete detail of Myelofibrosis market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Myelofibrosis Epidemiology Forecast

The Myelofibrosis epidemiology section covers insights about historical and current Myelofibrosis patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Myelofibrosis Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.  

 

Myelofibrosis Epidemiology Segmentation

• Total Incident Cases of Myelofibrosis
• Age-specific Incident Cases of Myelofibrosis
• Type-specific Incident Cases of Myelofibrosis
• Diagnosed and Diagnosed and Treatable cases of Myelofibrosis

As per DelveInsight, the Myelofibrosis market size shall grow during the forecast period owing to the increasing Incidence of Myelofibrosis in the 7MM.

 

Some of the key Myelofibrosis Companies involved in developing therapies include Sierra Oncology, Kartos Therapeutics, Prelude Therapeutics, Karyopharm Therapeutics, Suzhou Zelgen Biopharmaceuticals, and many others. Myelofibrosis Therapies covered in the report include KRT-232, PRT543, Selinexor, Momelotinib, Jaktinib hydrochloride tablets, And many more. 

 

For more details, visit: Myelofibrosis Market Growth